Amphastar Beats The Street For Third Consecutive Quarter
Firm Stands To Gain Further In H2 Following Pfizer Tornado Damage
Executive Summary
Amphastar has continued to surpass expectations for the third quarter in a row, as staggering growth of its glucagon injection propelled it to an 18% year-on-year revenue increase.